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EXPERIMENTAL STUDY
Long-term prophylactic insulin treatment can prevent
spontaneous diabetes and thyroiditis development
in the diabetes-prone bio-breeding rat, while
short-term treatment is ineffective
J Visser, F Klatter, L Vis, H Groen, J Strubbe1 and J Rozing
Department of Cell Biology, Immunology Section and 1 Department of Animal Physiology, University of Groningen, The Netherlands
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Abstract
Objective: Prophylactic insulin treatment has been demonstrated to reduce diabetes development in
the diabetes-prone bio-breeding (DP-BB) rat. These prophylactic insulin treatments were given from
50 to 150 days of age. However, several data indicate that the diabetogenic process in DP-BB rats
starts well before day 50.
Design and methods: DP-BB rats were given bovine insulin pellets from 21 to 60 days of age, from 21 to
100 days of age and from 60 to 100 days of age. At 160 days of age a glucose tolerance test was
performed to establish b-cell function and pancreata collected for histological analysis.
Results: Prophylactic insulin treatment from 21 to 100 days of age gave a 42% reduction of diabetes
incidence. The other treatment protocols had no effect. Non-diabetic rats treated with insulin from
day 21 to 100 showed normal glucose tolerance and no sign of insulitis at 160 days of age. Non-dia-
betic rats of the control group and the other treatment groups showed normal glucose tolerance, but
a slight increase of insulitis. Interestingly, the 21–100 day treated rats showed reduced serum levels
of anti-colloid antibodies as compared with the control group.
Conclusions: These results show that short-term prophylactic insulin treatment cannot prevent dia-
betes and thyroiditis development in DP-BB rats. The prophylactic treatment must start well before
60 days of age and be prolonged into the phase when the rats normally become diabetic to reduce
diabetes incidence. These findings imply that in the human situation prophylactic insulin treatment
must be prolonged over the normal range of diabetes onset.
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Introduction
The diabetes-prone bio-breeding (DP-BB) rat is a very
useful animal model of human insulin-dependent dia-
betes mellitus (IDDM). Like the human situation,
IDDM in the DP-BB rat is spontaneous and results in
the autoimmune destruction of the insulin-producing
b-cells of the pancreas (1).
Investigations into the etiology of IDDM suggest that
both genetic and environmental factors are involved
(2, 3). Important environmental factors in the develop-
ment of human IDDM are diet and viral infections
(2 –4).
DP-BB rats develop diabetes in a range from 60 to
120 days of age. This stage of disease development is
characterized by severe insulitis (1). The islets of
Langerhans are infiltrated by macrophages, natural
killer cells and cytotoxic T cells leading to destruction
of the b-cells (1). Cytokines, particularly the proinflam-
matory ones such as tumor necrosis factor (TNF)-a and
interleukin (IL)-1, are cytotoxic for b-cells and induce
the inflammatory cascade leading to b-cell destruction
(5, 6). Several reports show that increased expression of
proinflammatory cytokines such as IL-12, TNF-a, IL-1
and interferon-g is associated with b-cell destructive
insulitis, whereas non-destructive insulitis is more
associated with increased expression of anti-inflamma-
tory type 2 cytokines such as IL-10 and IL-4 and the
type 3 cytokine transforming growth factor-b (6–8).
Prophylactic insulin treatment has been shown to be
effective in the prevention of diabetes development in
animal models of diabetes such as the NOD mouse
and the BB rat (9). One of the mechanisms involved
in this protection is the induction of b-cell rest, which
causes a reduction of macrophage infiltration into the
islets of Langerhans and subsequently less b-cell
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destruction (9, 10). Other mechanisms are the induc-
tion of immunological tolerance or reduction of the
destructive autoimmune process by the induction of
anti-inflammatory cytokines (9).
Gotfredsen et al. (11) were the first to demonstrate
that life-long treatment with high doses of insulin
could protect DP-BB rats against diabetes. In addition,
Gottlieb et al. (12) demonstrated that only hypoglycemic
doses of insulin could protect anti-RT6 treated diabetes-
resistant (DR)-BB rats from becoming diabetic, while
lower doses were ineffective. In that study, activated
spleen cells of protected DR-BB rats were still able to
transfer diabetes, suggesting that the auto-reactive cell
population is still present, but functionally dormant,
in the treated animals (12). Taken together the exper-
iments performed by Gotfredsen et al. and Gottlieb et al.
suggest that in the DP-BB rat model of diabetes, protec-
tion by prophylactic insulin treatment works mainly via
the induction of b-cell rest (11, 12).
The prophylactic insulin treatments in the DP-BB rat
were given from 50 to 150 days of age, but several
data indicate that the autoimmune diabetogenic
process in DP-BB rats starts well before day 50 (1).
For example, in the DP-BB rat model of diabetes, an
early time interval has been identified in which dia-
betes can be prevented (1). Thymectomy of DP-BB
rats around 30 days of age prevents IDDM, whereas
thymectomy at day 60 has no effect (13). Accordingly,
injection with regulatory RT6þ T cells from DR-BB rats
in the period from 21 to 60 days of age prevents dia-
betes in DP-BB rats, while injection from 60 to 100
days does not influence the disease (14). Moreover,
timing of immunosuppressive therapy in the DP-BB
rat is crucial for the prevention of type 1 diabetes
(15). These findings indicate that the period between
21 and 60 days of age is critical for the development
of diabetes in DP-BB rats and the autoimmune process
can be stopped.
Interestingly, the beginning of this period starts with
the moment of weaning of the rats. Weaning is associ-
ated with a dramatic change in metabolic activity of
the animal. The rats change from mother’s milk to
solid food and have to increase their metabolic activity
to keep warm and for growth. In this period the
b-cells show a strong increase in number and activity
(16). Active b-cells are shown to be more visible for
the autoimmune response. Active b-cells are more
immunogenic and produce monocyte chemoattractant
protein (MCP)-1 and other chemokines (17 –19).
MCP-1 is a chemokine that attracts antigen-presenting
cells like macrophages and dendritic cells and activated
T cells (20). This means that in the period between 21
and 60 days, because of the increased activity of the
b-cell and the rise of the autoimmune response, the
DP-BB rat is the most vulnerable for the development
of IDDM. Inducing b-cell rest in this period might
protect the DP-BB rats against diabetes development
later in life.
For this purpose, we investigated whether a prophylac-
tic insulin treatment in this period can influence diabetes
development later in life as compared with a long-term
insulin treatment. Moreover, we investigated whether a




DP-BB and DR-BB rats were kept under viral antibody
free conditions in the Central Animal Facility of the
University of Groningen and fed standard chow
(Rodent Diet nr. Rmh-B2181; Hope Farms, Woerden,
The Netherlands) and acidified water freely. In this
study, rats from both sexes were used. In our colony
over 85% of the DP-BB rats spontaneously develop dia-
betes before 130 days of age, with no gender
differences.
All animals received humane care in compliance
with the principles of laboratory animal care (NIH pub-
lication no. 85-23, revised 1985) and the Dutch law on
experimental animal care.
Experimental protocol
In this study DP-BB rats were treated with bovine insu-
lin pellets (implanted s.c., release 1.5 –2 IU/24 h for 40
days; Linplant, Scarborough, Ontario, Canada) from 21
to 60 days of age, from 21 to 100 days of age and from
60 to 100 days of age. The dose (between 10 and
13.3 IU/kg body weight) supplied to the animals is
comparable with the dosages used in the studies by
Gottlieb et al. (11) and Gotfredsen et al. (12). At 160
days of age a glucose tolerance test was performed to
establish b-cell function in the remaining non-diabetic
rats and the pancreata were collected for histological
analysis.
Rats were weighed three times a week and screened
for hyperglycemia using blood glucose test strips
(Roche Diagnostics, Almere, The Netherlands). A
meter calculated the exact glucose concentration. The
used strips had the advantage that if the meter should
fail you always have a visual coloring of the strips allow-
ing an estimation of the glucose concentration. Rats
were diagnosed diabetic on the basis of a plasma glucose
concentration .11 mmol/l on two consecutive
occasions. Diagnosis was confirmed by histological
inspection of pancreatic tissue obtained at autopsy.
During the experiments none of the rats died of hypo-
glycemia. However, during a pilot experiment when we
were testing the insulin pellets, three rats died because
of hypoglycemia. This was due to the fact that the
animal-housing facility forgot to feed these rats
during the weekend. Therefore, we made sure that
the rats included in this study received enough food
and water during the experimental period.
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Pancreas histology
The degree of insulitis was calculated as described by
Visser et al. (4, 15). Upon autopsy, the pancreas was
removed, cleaned of fat and lymph nodes, fixed in
Bouin’s solution and processed for histological analysis.
Sections (7 microns) were stained with hematoxylin
and eosin for evaluation of macrophage/mononuclear
cell infiltration (insulitis) and degree of islet damage
using a Zeiss microscope. The degree of insulitis was
rated on a scale of 1–4 as follows: 1, normal islet
appearance and no infiltration; 2, mild insulitis
where macrophages/mononuclear cells are around,
but not in the islets; 3, severe insulitis, where macro-
phages/ mononuclear cells completely penetrate and
infiltrate the islets; 4, end-stage islets. Per pancreas sec-
tion an average histological insulitis score was calcu-
lated by adding up the histological insulitis score of
each islet and dividing it by the total number of islets
counted. Per section a minimum of five islets were
counted, depending on the diabetes status of the
animal; the number of islets per section ranged from
5 to 20. The analysis was performed independently
by two persons.
Glucose tolerance test
After an overnight fast from food, rats were injected i.p.
with 100 mg glucose per 100 g body weight using a
200 mg/ml glucose solution in water. Blood was
obtained by tail puncture just before and at 30, 60
and 120 min after the glucose injection.
Detection of anti-colloid autoantibodies
Anti-colloid antibodies in the serum were detected
using the indirect immunofluorescence technique.
Six-micron thin frozen porcine thyroid sections were
cut, air dried overnight and fixed in cold acetone
(220 8C) for 10 min. The sections were preincubated
with normal rabbit serum (Dako, Glostrup, Denmark)
(diluted 50-fold in PBS with 1% BSA) for 10 min.
The sections were incubated with several dilutions of
the rat serum (rat sera were diluted in PBS as indicated
in Table 2). After washing in PBS, the sections were
incubated with FITC-labeled rabbit anti-rat immuno-
globulins (Dako) diluted 25-fold in PBS/1% BSA for
30 min. After this second step the slides were washed
in PBS and embedded in aquamount (Gurr, BDH
limited, Poole, Dorset, UK) and examined using a fluor-
escence microscope. Three control slides were
included: one without incubation of rat serum,
another incubated with a serum previously scored as
negative and one with a rat serum previously scored
as positive. The staining intensity was arbitrarily and
blindly scored by two independent persons as negative,
positive, strong positive and very strong positive. The
titer was set as the last dilution at which the serum
scored positive.
Statistical analysis
The product limit method of Kaplan and Meier was
used to estimate diabetes incidence. Diabetes incidences
in the test groups at 160 days of age were compared
using the chi-square test. The mean insulitis scores
and the autoantibody titers of the groups were com-
pared using the Mann–Whitney U test. We considered
P values less than 0.05 to be significant. For statistical
analysis the SPSS 8.0 software package for Windows
was used.
Results
Short-term prophylactic insulin treatment
has no effect on diabetes development, whereas
a long-term insulin treatment gave a
reduction of 42%
As shown in Fig. 1, short-term prophylactic insulin
treatment from day 21 to 60 has no effect on the dia-
betes development later in life. The treatment has no
effect on diabetes onset and the diabetes incidence.
When the pellets are no longer releasing insulin, the
rats that have become diabetic between day 60 and
100 will show an increase in blood glucose levels.
Indeed, around 100 days of age the first animals in
the long-term treated group have blood glucose levels
exceeding 11 mmol/l. The slope of the curve of the
long-term treated group is comparable with the slope
of the curve from the control group. However, the
Figure 1 Long-term insulin treatment prevents diabetes
development in DP-BB rats, whereas short-term treatment does
not. DP-BB rats were treated with bovine insulin pellets (implanted
s.c., release 1.5–2 IU/24 h for 40 days) from 21 to 60 days of age
(X; n ¼ 11), from 60 to 100 days of age (B; n ¼ 12) and from 21
to 100 days of age (O; n ¼ 23). The diabetes development was
compared with control rats that received a placebo pellet
(S; n ¼ 23). At 160 days of age, significance of the difference
in diabetes incidence was calculated using the chi-square test.
*P , 0.05 as compared with the control group.
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insulin treatment from day 21 to 100 gives a
reduction of approximately 42% in diabetes incidence
at day 160 as compared with the control group
(P ¼ 0.01, chi-square test). The rats that were treated
with insulin from day 60 to 100 showed no reduction
in diabetes development (P ¼ 0.13, chi-square test).
Animals on prophylactic insulin therapy
display reduced blood glucose levels, but no
severe hypoglycemia
In view of the fact that insulin therapy can cause severe
hypoglycemia, we monitored four rats treated with
insulin from day 21 to 100, four rats treated with insu-
lin from day 60 to 100 and two control rats. The rats
were monitored from day 36 to 90. As shown in
Fig. 2, rats receiving insulin therapy have on average
reduced blood glucose levels, but their levels did not
drop below the 2.1 mmol/l.
Animals protected by long-term insulin
treatment show a normal glucose tolerance
and have no signs of insulitis at 160 days of
age
At 160 days of age, four of the non-diabetic long-term
insulin treated rats, one non-diabetic control rat and
one diabetic rat were exposed to the glucose tolerance
test as described in the Materials and methods section.
As demonstrated in Fig. 3, the non-diabetic control rat
showed a good glucose tolerance. Three of the four
non-diabetic rats from the long-term insulin treated
group showed a comparable glucose tolerance. How-
ever, one rat of this group showed a reduced glucose
tolerance. The diabetic rat displayed no glucose
tolerance.
At 160 days of age, the experiment was ended. The
pancreas was removed from the non-diabetic rats and
studied for histological signs of insulitis. As demon-
strated in Table 1, the non-diabetic rats of the long-
term treated group showed almost no signs of insulitis.
The insulitis score of these rats was only slightly higher
than the insulitis score detected in 56-day-old non-dia-
betic DP-BB rats or DR-BB rats.
Interestingly, the two remaining non-diabetic rats of
the short-term treated group showed increased signs
of insulitis as compared with the non-diabetic rats of
the other groups.
Long-term prophylactic insulin treatment
reduces serum levels of anti-colloid
autoantibodies in the DP-BB rat
Besides the effect of the insulin treatment on diabetes
development we also studied the effect of the prophylac-
tic insulin treatment on the development of thyroiditis.
In DP-BB rats thyroiditis development is associated with
diabetes development (1). We measured the levels of
anti-colloid autoantibodies in the serum of DP-BB rats
older than 80 days that received insulin from day 21
to 100 and from day 60 to 100. We compared these
levels with untreated DP-BB rats over 80 days of age.
As shown in Table 2, the DP-BB rats treated with
insulin from day 21 to 100 have reduced levels of
anti-colloid autoantibodies in their serum as compared
with the untreated DP-BB rats and the DP-BB rats that
received insulin from day 60 to 100 (P , 0.05, Mann–
Whitney U test). From the long-term treated rats, only
four of the nine rats showed detectable levels of anti-
colloid antibodies. Moreover, in these rats the autoanti-
bodies were only detectable in the undiluted samples,
Figure 2 Animals under prophylactic insulin therapy display
reduced blood glucose levels, but no severe hypoglycemia.
DP-BB rats were treated with bovine insulin pellets (implanted
s.c., release 1.5–2 IU/24 h for 40 days) from 21 to 100 days of
age (K; n ¼ 4) and from 60 to 100 days of age (B; n ¼ 4). The
diabetes development was compared with two control rats
(V and S) which received a placebo pellet.
Figure 3 Glucose tolerance of the prophylactic insulin treated
rats. At 160 days of age, four of the non-diabetic long-term insulin
treated rats, one non-diabetic control rat and one diabetic rat
were exposed to the glucose tolerance test as described in the
Materials and methods section. Three of the four non-diabetic
21-100 day treated rats showed a glucose tolerance comparable
with the control rat. Although one rat showed a reduced glucose
tolerance, it did not exceed the 11 mmol/l like the diabetic rat
which showed no glucose tolerance.
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while in the other groups, some individual rats had
detectable autoantibodies in 100-fold diluted serum.
As is shown in Table 2, the diabetic animals did not
display higher titers of anti-colloid autoantibodies than
the non-diabetic animals.
Discussion
In this paper it is demonstrated that a short-term insu-
lin treatment between 21 and 60 days of age does not
influence diabetes development in the DP-BB rat. How-
ever, long-term insulin treatment from day 21 to 100
gave a reduction of approximately 42% in diabetes inci-
dence at 160 days of age. Accordingly, protected long-
term treated rats showed normal glucose tolerance and
minimal to no signs of insulitis. Interestingly, long-term
treated rats showed reduced serum levels of anti-colloid
autoantibodies as compared with the control rats.
What might be the mechanisms involved in the anti-
diabetogenic effect of the long-term prophylactic insulin
treatment? Previous research has indicated that for this
anti-diabetogenic effect, the activity of the b-cell is very
important. For instance, Janssen et al. (10) demon-
strated in the NOD mouse model of diabetes that induc-
tion of b-cell rest by prophylactic insulin treatment
reduces the infiltration of destructive macrophages
into the islets of Langerhans. It is thought that this
influx of macrophages and or dendritic cells is a
normal phenomenon and the b-cell needs to be
nurtured by these cells (H Drexhage, Erasmus Univer-
sity, The Netherlands, personal communication). Pro-
duction of chemokines like MCP-1 may be involved in
this process, because it has been shown that active
b-cells can produce MCP-1 (17 –19). This production
of MCP-1 and other chemokines can be increased by
exposure of the b-cells to inflammatory cytokines like
IL-1 and TNF-a (17 –19). Therefore, it is acceptable
to hypothesize that when the b-cells are kept quiet by
exogenous insulin, they might produce less or no che-
mokines, and the macrophages, dendritic cells and T
cells will not be attracted to the islets of Langerhans.
Table 1 Histological insulitis score and number of islets per pancreas section of the diabetic and non-diabetic BB rats in the different
treatment groups. The data are expressed as means^S.D.
Diabetic Non-diabetic at 160 days of age
Treatment (n) Insulitis score (n) Number of islets Insulitis score (n) Number of islets
Control (23) 2.73^0.68 (18) 6.75^2.79 1.41^0.68 (5) 12^4.95
Insulin day 21–60 (11) nd (9) — 1.96^0.02 (2)* 10^1.41**
Insulin day 21–100 (23) 2.48^0.36 (11) 6.60^1.67 1.19^0.15 (12)*** 14.92^4.35
Healthy 56-day-old DP-BB (3) — — 1.02^0.03 (3) 18.33^1.53#
* P , 0.05 as compared with insulin day 21–100 and the healthy DP-BB rats.
** P , 0.05 as compared with the healthy DP-BB rats.
*** P , 0.05 as compared with insulin day 21–60 DP-BB rats.
# P , 0.05 as compared with insulin day 21–60 and the control DP-BB rats.
Table 2 Presence of anti-colloid antibodies in serum of DP-BB
rats after prophylactic insulin treatment. Titers are expressed as
means^S.D.
Dilution of serum
Undiluted 5£ 10£ 20£ 50£ 100£ Titer
DP-BB rats .80 days of age (control group)
1 (100)# þþþ nd þþ þþ þ 2 50
2 (105)# þ 2 2 2 2 2 1
3 (99)# þ 2 2 2 2 2 1
4 (98)# þ 2 2 2 2 2 1
5 (100)# þ 2 2 2 2 2 1
6 (100)# þ þ 2 2 2 2 1
7 (130) þ nd 2 2 2 2 1
8 (130) þ nd þ 2 2 2 10
9 (130) þþþ nd þ þ 2 2 20
10 (130) þþ nd þ þ 2 2 20
Mean 11^5
DP-BB rats treated with insulin from 60 to 100 days of age
11 (100)# þþþ þþþ þþ þþ þ þ 100
12 (97)# þþ þ 2 2 2 2 5
13 (104)# þþþ þþþ þþ þ þ þ 100
14 (160)# 2 2 2 2 2 2 0
15 (180) þ þ 2 2 2 2 5
16 (139)# 2 2 2 2 2 2 0
17 (180) þ þ 2 2 2 2 5
18 (130)# þþ þ þ 2 2 2 10
19 (160) þþþ þþþ þþ þ þ 2 50
20 (160) þ 2 2 2 2 2 1
21 (100)# þ 2 2 2 2 2 1
22 (98)# þ 2 2 2 2 2 1
Mean 23^11
DP-BB rats treated with insulin from 21 to 100 days of age
23 (191) 2 2 2 2 2 2 0
24 (121)# 2 2 2 2 2 2 0
25 (191) 2 2 2 2 2 2 0
26 (191) 2 2 2 2 2 2 0
27 (100)# þ 2 2 2 2 2 1
28 (191) þ 2 2 2 2 2 1
29 (114)# þ 2 2 2 2 2 1
30 (100)# þ 2 2 2 2 2 1
31 (100)# þ 2 2 2 2 2 1
Mean 0.6^0.2*
* P , 0.05 as compared with the control group and the rats treated with
insulin from day 60 to 100. The control group does not differ from the
60–100 day insulin treated group.
þþþ , very strong positive; þþ , strong positive; þ , positive; 2 , negative.
# Diabetic rat.
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Interestingly, insulin itself has anti-inflammatory
properties. It was demonstrated that insulin could sup-
press the induction of the transcription factor NFkB that
is important for the induction of proinflammatory cyto-
kines and chemokines (20, 21). Moreover, insulin was
demonstrated to suppress the production of MCP-1 (22).
Another mechanism might be the fact that insulin
treatment makes the b-cells less immunogenic, as was
demonstrated by Anastasi et al. (23). Accordingly,
Aaen et al. (24) showed that b-cells activated in vitro
by high glucose levels express higher densities of
b-cell associated antigens.
Induction of tolerance to insulin is thought not to be
dominantly involved in parental prophylactic insulin
treatment, but to be the key mechanism in the preven-
tion of diabetes by oral insulin therapy (9).
In our experiments the rats on insulin therapy
showed on average a reduced blood glucose level.
This indicates that the b-cells of these rats were less
activated by glucose. Therefore, in our experiments
the dominant protective mechanism might be induc-
tion of b-cell rest, but the other protective mechanisms
as described above may be involved as well.
Besides diabetes, DP-BB rats also develop thyroiditis
(25). When DP-BB rats are over 90 days of age, they
start to show histological signs of thyroiditis (25). How-
ever, at that age most of the DP-BB rats have developed
diabetes. Diabetes development in DP-BB rats is very
acute and the rats can die of hyperglycemia in a few
days. Therefore, the rats must be monitored at least
three or four times a week to prevent unnecessary
deaths by hyperglycemia. To study thyroiditis develop-
ment in DP-BB rats, most researchers treat the DP-BB
rats with insulin at the moment of diabetes onset (25).
We have demonstrated in this paper that DP-BB rats
can be treated with insulin-releasing pellets just before
they start to develop diabetes (at 60 days of age), with-
out affecting the levels of anti-colloid autoantibodies.
Unfortunately, we could not correlate the titers of
anti-colloid autoantibodies with histological signs of
thyroiditis. DP-BB rats mainly develop histological
signs of thyroiditis when they are put on an iodine-
enriched diet. Since our rats were kept on standard
diets, they did not develop histological signs of thyroid-
itis. However, rats kept on standard diets can still show
elevated titers of anti-colloid autoantibodies (26).
Because expression of anti-colloid autoantibodies is
strongly associated with thyroiditis development (25),
it is acceptable to hypothesize that treatment with insu-
lin from 60 days of age has no effect on thyroiditis
development. The fact that we found histological
signs of thyroiditis in a 100-day-old DP-BB rat treated
with insulin from day 60 to 100 (rat 11, Table 2) sup-
ports this hypothesis. However, treating the rats with
insulin from day 21 to 100 gives a reduction of
serum anti-colloid autoantibody levels. Therefore we
state that long-term treatment with insulin might influ-
ence the development of thyroiditis in the DP-BB rat.
Taken together, diabetes development in humans and
the DP-BB rat is multifactorial. The immune system,
b-cell functionality, viral infections and diabetogenic
food antigens are the key players in diabetes develop-
ment (1–4). This multifactoriality can explain why
the timing and duration of the insulin treatment has
differential effects on the diabetes development in the
DP-BB rat. We have demonstrated that short-term insu-
lin treatment in the diabetes-sensitive period between
21 and 60 days is not sufficient to prevent diabetes in
the DP-BB rat. The prophylactic insulin treatment has
to start well before the onset of diabetes development
and be prolonged into the phase when the rats nor-
mally become diabetic.
Finally, these results show that with regard to the
human situation, treatment with insulin has thera-
peutic potential. However, recent clinical trials
showed that prophylactic insulin therapy in first-
degree relatives of type 1 diabetics could not prevent
diabetes development (27). In these trials, low-dose
insulin treatment was used (27). In our animal model
and the other animal models high-dose insulin therapy
is used (9). In view of our results, employing high-dose
prophylactic insulin therapy in children at risk for
developing diabetes might be promising. However,
high-dose insulin therapy may have severe side-effects
like hypoglycemia and subsequently reduced cognitive
functions (27). Therefore, optimal dose and safety has
to be established before employing high-dose prophy-
lactic insulin therapy.
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